Efficacy evaluation of a bivalent subunit vaccine against classical swine fever virus and porcine circovirus type 2

Yu-San Chen,Chang-Ye Lee,Chi-Chien Wu,Pei-Lun Kao,Tai-An Chen,Yahui Huang,Wen-Bin Chung,Tsun‑Yung Kuo,Charles Chen

DOI: https://doi.org/10.1038/s41598-024-53624-w

IF: 4.6

2024-02-07

Scientific Reports

Abstract:Classical swine fever virus (CSFV) and porcine circovirus type 2 (PCV2) are two of the most devastating and economically significant pathogens affecting pig populations worldwide. Administration of a combination of vaccines against swine pathogens has been demonstrated to be as efficacious as the administration of single vaccines. In this study, we developed and tested a novel bivalent subunit vaccine against CSFV and PCV2. The safety and efficacy of this vaccine were demonstrated in mice and specific pathogen-free (SPF) piglets. In addition to investigating the serological responses after immunization, challenge studies with both viruses were also conducted. The results showed that this CSFV/PCV2 bivalent vaccine elicited a high level of neutralizing antibodies against both viruses and provided protection in challenge studies. In conclusion, the CSFV/PCV2 bivalent vaccine is safe and effective against CSFV or PCV2 challenge.

multidisciplinary sciences

What problem does this paper attempt to address?

The main objective of this paper is to develop and evaluate a novel bivalent subunit vaccine aimed at combating Classical Swine Fever Virus (CSFV) and Porcine Circovirus type 2 (PCV2). Both of these viruses are pathogens that have a significant impact on the global swine industry.

The bivalent vaccine developed in the study contains the E2 protein of CSFV and the ORF2 protein of PCV2. These proteins are produced through mammalian cell expression systems (CHO cells) and insect cell expression systems (using baculovirus vectors), respectively. The study first validated the safety and immunogenicity of this bivalent vaccine in a mouse model and further evaluated the safety and protective efficacy of the vaccine in Specific Pathogen-Free (SPF) piglets.

The main results indicate:
- The bivalent vaccine can induce highly neutralizing antibodies against CSFV and PCV2.
- In CSFV or PCV2 challenge experiments, pigs vaccinated with the bivalent vaccine showed significant protection, including reduced clinical symptoms, normal body temperature, and lower viral loads.
- No severe adverse reactions were observed after vaccination.

In summary, this study demonstrates the efficacy and safety of the novel CSFV/PCV2 bivalent subunit vaccine, providing a potential solution for controlling these two important swine diseases.